مورد إلكتروني
Phase I study of paclitaxel and oral etoposide in previously uutreated non-small-cell and extensive small-cell lung cancer.
| العنوان: | Phase I study of paclitaxel and oral etoposide in previously uutreated non-small-cell and extensive small-cell lung cancer. |
|---|---|
| المؤلفون: | Boyer M.J., Zalcberg J., Olver I.N., Millward M.J., Richardson G., McKeage M.J. |
| بيانات النشر: | Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom) Netherlands 2012-10-22 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Purpose: This phase I study of paclitaxel and oral etoposide was performed to determine the safety of the combination in patients with advanced lung cancer who had received no prior chemotherapy, and to identify a dose for phase II testing. Patients and Methods: Patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) or extensive small- cell lung cancer (SCLC), who had received no prior chemotherapy were treated with intravenous paclitaxel given as a three hour infusion (starting dose 100 mg/m2) and oral etoposide, 100 mg daily for five days. Two schedules of administration were used with the paclitaxel given on day 1 (schedule A) or day 5 (schedule B) of a 21 day cycle. Result(s): Forty-nine patients were entered on the study, four of whom had SCLC. All patients were evaluable for toxicity. The maximum tolerated dose was paclitaxel 200 mg/m2 on day, in combination with oral etoposide 100 mg daily on days 1 to 5 (schedule A). The dose limiting toxicities were mucositis, myalgia, diarrhoea, and paraesthesiae. Using schedule B, myelosuppression, with febrile neutropenia was dose limiting at a paclitaxel dose of 160 mg/m2. Amongst the 45 patients with NSCLC there were three complete and eight partial responses (24%; 95% CI 13%-40%), while there was one complete response in the four patients with SCLC. Conclusion(s): Paclitaxel 200 mg/m2 on day 1, with oral etoposide 100 mg daily on days 1 to 5 can be administered safely, and is the recommended dose for phase II studies. |
| مصطلحات الفهرس: | lung small cell cancer/dt [Drug Therapy], male, neurotoxicity/si [Side Effect], neutropenia/di [Diagnosis], neutropenia/si [Side Effect], oral drug administration, phase 1 clinical trial, priority journal, thorax radiography, etoposide/ae [Adverse Drug Reaction], etoposide/ct [Clinical Trial], etoposide/ad [Drug Administration], etoposide/cb [Drug Combination], etoposide/do [Drug Dose], etoposide/dt [Drug Therapy], etoposide/pr [Pharmaceutics], paclitaxel/ae [Adverse Drug Reaction], paclitaxel/ct [Clinical Trial], paclitaxel/ad [Drug Administration], paclitaxel/cb [Drug Combination], paclitaxel/do [Drug Dose], paclitaxel/dt [Drug Therapy], clinical article, adult, aged, article, blood cell count, blood toxicity/di [Diagnosis], cancer survival, blood toxicity/si [Side Effect], clinical trial, computer assisted tomography, drug safety, female, human, hypersensitivity/si [Side Effect], leukopenia/di [Diagnosis], leukopenia/si [Side Effect], lung non small cell cancer/di [Diagnosis], lung non small cell cancer/dt [Drug Therapy], lung small cell cancer/di [Diagnosis], Article |
| URL: | Click here for full text options LibKey Link |
| الإتاحة: | Open access content. Open access content Copyright 2012 Elsevier B.V., All rights reserved. |
| أرقام أخرى: | AUSHL oai:repository.monashhealth.org:1/33822 Annals of Oncology. 8 (5) (pp 485-489), 1997. Date of Publication: May 1997. 0923-7534 https://repository.monashhealth.org/monashhealthjspui/handle/1/33822 9233529 [http://www.ncbi.nlm.nih.gov/pubmed/?term=9233529] 27310694 (Boyer) Royal Prince Alfred Hospital, Sydney, NSW, Australia (Zalcberg) Austin and Repatriation Med. Centre, Melbourne, Vic., Australia (Olver) Royal Adelaide Hospital, Adelaide, SA, Australia (Millward) Peter MacCallum Cancer Institute, Melbourne, Vic., Australia (Richardson) Monash Medical Centre, Melbourne, Vic., Australia (McKeage) Prince of Wales Hospital, Sydney, NSW, Australia (McKeage) Univ. of Auckland Medical School, Auckland, New Zealand (Boyer) Department of Medical Oncology, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia 1305137468 |
| المصدر المساهم: | MONASH HEALTH LIBRS From OAIster®, provided by the OCLC Cooperative. |
| رقم الأكسشن: | edsoai.on1305137468 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |